Literature DB >> 21624412

Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.

Maria Paulke-Korinek1, Gustav Fischmeister, Ana Grac, Pamela Rendi-Wagner, Michael Kundi, Afsaneh Mohsenzadeh-Rabbani, Katharina Moritz, Beate Fenninger, Reinhart Jarisch, Joanna Jasinska, Heidemarie Holzmann, Ursula Wiedermann, Herwig Kollaritsch.   

Abstract

To determine the proficiency of the Austrian childhood vaccination schedule to induce long lasting seroprotection against vaccine preventable diseases a seroepidemiological study in 348 children between four and eight years of age was conducted. Antibodies against diphtheria, tetanus, pertussis, hepatitis B, measles, mumps and rubella antigens were assessed in children, who had been vaccinated with hexavalent DTaP-HBV-IPV/Hib vaccines at three, four, five months and in the second year of life and/or MMR vaccines in the second year of life at least once, but mostly twice. High seroprotection rates (SPRs) were detected for tetanus (96%) and measles (90%). SPRs regarding diphtheria and mumps were 81% and 72%, respectively. Rubella-SPRs were 68% in females and 58% in males. Hepatitis B-antibody levels ≥10 mIU/mL were present in 52%; antibodies against pertussis were detected in 27% of the children. SPRs for measles and rubella depended on the interval since last vaccination; mumps-antibodies were significantly lower after one MMR-vaccination only. Antibodies against diphtheria, tetanus and pertussis depended on the interval since last vaccination while HBs-antibodies did not. The low levels of antibodies 1-7 years after vaccination against pertussis, rubella and mumps after only one vaccination should be considered when recommending new vaccination schedules.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624412     DOI: 10.1016/j.vaccine.2011.05.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Long time immunogenicity of measles vaccine in the vaccination era: An open question.

Authors:  Maria Serena Gallone; Cinzia Germinario; Angela Larocca; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2016-09-26       Impact factor: 3.452

2.  Impaired Antigen-Specific Immune Response to Vaccines in Children with Antibody Production Defects.

Authors:  Aleksandra Szczawinska-Poplonyk; Anna Breborowicz; Husam Samara; Lidia Ossowska; Grzegorz Dworacki
Journal:  Clin Vaccine Immunol       Date:  2015-05-27

3.  Genetic Variation of Bordetella pertussis in Austria.

Authors:  Birgit Wagner; Helen Melzer; Georg Freymüller; Sabine Stumvoll; Pamela Rendi-Wagner; Maria Paulke-Korinek; Andreas Repa; Frits R Mooi; Herwig Kollaritsch; Helmut Mittermayer; Harald H Kessler; Gerold Stanek; Ralf Steinborn; Michael Duchêne; Ursula Wiedermann
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

Review 4.  Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).

Authors:  Esmeralda Núñez Cuadros; Joan Calzada-Hernández; Daniel Clemente; Sara Guillén Martín; Laura Fernández Silveira; María José Lirola-Cruz; Alfredo Tagarro; Marisol Camacho Lovillo; Rosa María Alcobendas Rueda; Agustín López López; Miren Satrustegi Aritziturri; Cristina Calvo
Journal:  Eur J Pediatr       Date:  2022-03-08       Impact factor: 3.860

Review 5.  Eradication of measles: remaining challenges.

Authors:  Heidemarie Holzmann; Hartmut Hengel; Matthias Tenbusch; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2016-03-02       Impact factor: 3.402

6.  Does vaccination ensure protection? Assessing diphtheria and tetanus antibody levels in a population of healthy children: A cross-sectional study.

Authors:  Ewelina Gowin; Jacek Wysocki; Ewelina Kałużna; Bogna Świątek-Kościelna; Joanna Wysocka-Leszczyńska; Michał Michalak; Danuta Januszkiewicz-Lewandowska
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.